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bined with current cervical cancer screening and HPV disease treatment practices
in Turkey. For the vaccination strategy 85% coverage rate was assumed in the
frame of a mandatory school-based program. Reference strategy was current cer-
vical cancer screening and HPV disease treatment practices in Turkey. Costs were
estimated from the perspective of the Turkish healthcare system, using direct
medical costs associated with the diagnosis and treatment of cervical diseases.
RESULTS: Over 100 years, cumulative % (absolute) reduction in the incidence of
6/11/16/18-related cases of CIN1, CIN2/3, cervical cancer, cervical cancer deaths,
genital warts-female, and genital-warts-male was 78% (4,894), 72% (32,537), 57%
(73,277), 54% (40,513), 86% (404,674), and 86% (409,029), respectively, in the vacci-
nation group compared to the reference group. Number of 6/11/16/18-related CIN1,
CIN2/3, cervical cancer, cervical cancer deaths, and genital warts (both in female
and male population) was halved in the vaccination strategy group compared to
the reference strategy group by year 19, 24, 41, 44, and 14, respectively. The incre-
mental cost-effectiveness ratio for routine vaccination of 12-year-old girls was
18,251 TRY/QALY over 100 years. CONCLUSIONS: A quadrivalent HPV vaccination
program can reduce the incidence of cervical cancer, CINs and genital warts in
Turkey at a cost-per-QALY ratio within the range defined as cost effective.
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OBJECTIVES: Sarcomas are rare tumours (1-2% of all cancers) with high discor-
dance in diagnosis and low compliance with clinical practice guidelines (CPG). The
objective was then to perform a cost-effectiveness analysis (CEA) of compliance
with CPG compared to non compliance in the treatment of sarcoma. METHODS:
The study included patients aged15 years with histological diagnosis of sarcoma
treated at the University hospital of Lyon and/or Léon Bérard Cancer centre (Rhône-
Alpes region, France) in 2005/2006 or in public hospitals of Veneto (Italy) in 2007.
The time horizon was three years post diagnosis. The hospital’s perspective was
adopted, based on a microcosting approach. All costs were expressed in euros 2009.
A 4% annual discount rate was applied to both costs and effects. Incremental Cost
Effectiveness Ratios (ICER) were expressed as costs per life year gained, per disease-
free year gained, and per relapse-free year gained when treatments were compli-
ant with CPG compared to not compliant. Probabilistic sensitivity analyses were
performed based on 10000 bootstrap replications both with and without adjusting
data to grade. RESULTS: A total of 219 patients were included in the study. Com-
pliance with CPG was observed for 118 patients (54%). Average total costs reached
€23,571 when treatment was in accordance with CPG and €27,313 otherwise. Com-
pliance with CPG strictly dominates for disease-free and relapse-free survivals.
When handling uncertainty, probabilities that compliance with CPG still strictly
dominates were 33%, 63% and 88% for overall, disease-free, and relapse-free sur-
vivals, respectively. When costs and effects were adjusted to grade, probabilities
reached 17%, 48% and 75%, respectively. CONCLUSIONS: Given that few cost-ef-
fectiveness analyses have examined compliance with CPG in rare tumours, these
results are promising and should encourage physicians’ efforts to increase their
compliance to CPG.
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OBJECTIVES: To estimate the cost-effectiveness of G-CSF PP strategies versus peg-
filgrastim SP and G-CSF SP strategies versus no prophylaxis for decreasing FN
incidence in patients treated with cytotoxic chemotherapy for stages 2 and 3 breast
cancer. METHODS: A Markov model was designed to track health outcomes (FN
events) and medical direct costs (G-CSF, administration and FN episode costs, cal-
culated with French Sickness Fund perspective). The model compared 9 prophy-
laxis strategies for three frequent BC chemotherapies (TAC [docetaxel, doxorubi-
cin, cyclophosphamide], TC [docetaxel, cyclophosphamide] and AC-T
[doxorubicin, cyclophosphamide—docetaxel]): pegfilgrastim (Neulasta®), 6-day
filgrastim (Neupogen®), 11-day filgrastim, 6-day lenograstim, as either PP (initiated
from first cycle) or SP (initiated after FN event), or no prophylaxis. Inputs included
transition probabilities (relative FN risks depending on the chemotherapy, deter-
mined from expert opinion and published studies: TAC, 25%; TC, 10% and AC-T 7%
for AC and 21% for T), FN history and chemotherapy cycle), as well as unit costs for
prophylaxis resources and overall cost associated with FN. Incremental cost-effec-
tiveness ratios (ICERs) were expressed per FN event avoided. PP strategies were
compared to SP with pegfilgrastim and SP strategies were compared to no
prophylaxis. RESULTS: In the high risk population (chemotherapy FN risk 20%),
PP-pegfilgrastim was the most cost-effective PP-G-CSF versus SP-pegfilgrastim.
With TAC, ICER was €8,383 per FN avoided. In less cytotoxic regimens without
considering patient risk factors, after an FN event, SP-pegfilgrastim was the most
cost-effective SP-G-CSF compared to no prophylaxis, with ICERS ranging from
€4614 with TC to €4795 with AC-T.CONCLUSIONS:According to our model based on
French cost data, pegfilgrastim in PP and SP is more cost-effective than PP and SP
with filgrastim and lenograstim in BC. PP-pegfilgrastim is the most cost-effective PP
strategy in case of high risk of FN.
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OBJECTIVES: Colorectal cancer (CRC) is one of the most prevalent forms of cancer
worldwide. This review aims to report on the most recent clinical and cost-effec-
tiveness data available for five of the most often used drugs in the treatment of
advanced (ACRC) and non-advanced CRC; oxaliplatin, irinotecan, bevacizumab,
panitumumab and cetuximab. METHODS: A systematic review of the literature
was performed for the clinical effectiveness. Articles were divided on type of CRC,
ACRC or non-advanced CRC , and for ACRC on time point of treatment (1st, 2nd or
3rd line). If possible, data on overall survival (OS) and progression free survival (PFS)
were extracted. An additional systematic review was performed to identify cost-
effectiveness analyses performed for non-advanced CRC and ACRC, from which
total costs, total gains (LYG or QALYs) and ICERs were extracted. RESULTS: Regard-
ing clinical effectiveness, our search identified seven articles for oxaliplatin, six for
irinotecan, four for bevacizumab five for cetuximab and four for panitumumab.
The cost-effectiveness search yielded 6 articles for non-advanced CRC and 17 arti-
cles for ACRC. Clinical effectiveness has been demonstrated in the literature for
oxaliplatin, irinotecan and bevacizumab, with on average approximately two to
three months additional survival. Effectivness of panitumumab and cetuximab has
mainly been demonstrated on PFS, where on average 2 months is gained. The ICERs
of oxaliplatin for non-advanced CRC were between £2,970 and $24,104/QALY. ICERs
reported oxaliplatin and irinotecan combination therapy vs monotherapy with
5-FUin ACRC are between $10,137/LYG and £58.400/progression free LYG. ICERs for
bevacizumab, cetuximab and panitumub in addition to combination chemother-
apy in advanced CRC, when reported, are between €17.000/LYG and $299,613/QALY
CONCLUSIONS: Clinical effectiveness of oxaliplatin, irinotecan, bevacizumab, ce-
tuximab and panitumab has been established. However, it is not clear whether the
use of these drugs is also cost-effective, especially not for bevacizumab, cetuximab
and panitumumab.
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OBJECTIVES: Weekly gemcitabin and erlotinib are both active in elderly patients
treated for NSCLC. The aim of the GFPC0505 randomized phase II trial was to
compare the efficacy and the cost of weekly gemcitabin (G) followed by erlotinib
after progression (arm A) versus erlotinib followed by G after progression (arm B) in
frail elderly patients with advanced non small-cell lung cancer (NSCLC), selected
on the basis of a comprehensive geriatric assessment (CGA). METHODS: Frail el-
derly chemotherapy-naive patients with stage IIIB/IV NSCLC were selected after a
CGA. Main clinical outcome was time to second progression (TTP2). Costs were
limited to direct medical costs and were prospectively collected until progression,
from the third party payer perspective. Health utilities (based on disease states and
grade 3-4 toxicities) and costs after progression were derived from the literature.
Sensitivity analyses were performed. RESULTS: Median age of the 94 enrolled pa-
tients was 78.2 years, and 76 (80%) were male. There is no significantly difference
between the 44 and 50 patients respectively randomized in arm A and B, in terms of
efficacy (TTP2: 4.3 and 3.5 months: overall survival: 4.4 and 3.9 months, mean
QALY:0.347 and 0.325) and in terms of mean direct costs (15,363 and 15,233€).
CONCLUSIONS: In this population, the 2 strategies appeared equivalent in terms of
efficacy and costs. Supported by an unrestricted educational grant from Roche
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OBJECTIVES: To evaluate whether the use of bevacizumab  paclitaxel offers best
cost-effective results regarding the use of paclitaxel for patients with metastatic
breast cancer mBC METHODS: The treatment was evaluated up to the progression
of the disease, rescue management and palliative up to to death in a Markov model,
operating 65 cycles of 28 days. An incremental cost effectiveness analysis and
sensitivity analysis was performed considering as an outcome measure progres-
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